Ameeta E. Singh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ameeta E. Singh has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Tom Wong
Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Ottawa
3 shared publicationsBarbara Romanowski
2 shared publicationsJutta K. Preiksaitis
University of Alberta, Provincial Laboratory for Public Health, Edmonton, Alberta, Canada
2 shared publicationsSabrina S. Plitt
Centre for Infectious Disease Prevention and Control, Public Health Agency of Canada, Ottawa, Canada
2 shared publicationsAlex Ferenczy
Provincial Laboratory for Public Health, Edmonton, Alberta
1 shared publication- Ali Mohammed Somily
Department of Pathology and Laboratory Medicine, College of Medicine, King Saud University, King Saud University Medical City, Riyadh 11451, Saudi Arabia
1 shared publication
Latest Publications
- 1 October 2017
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 44 (10) , 627-629
Trichomonas vaginalis Prevalence and Correlates in Women and Men Attending STI Clinics in Western Canada
Trichomonas vaginalis prevalence (2.8%) in female sexually transmitted infection clinic attendees was within the prevalence of chlamydia (5.8%) and gonorrhea (1.8%), while being very low for male attendees (0.2%). Correlates among women were indigenous ethnicity, other ethnicity, and being symptomatic.
- 1 October 2017
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 44 (10) , 627-629
Trichomonas vaginalis Prevalence and Correlates in Women and Men Attending STI Clinics in Western Canada
Trichomonas vaginalis prevalence (2.8%) in female sexually transmitted infection clinic attendees was within the prevalence of chlamydia (5.8%) and gonorrhea (1.8%), while being very low for male attendees (0.2%). Correlates among women were indigenous ethnicity, other ethnicity, and being symptomatic.
- 1 July 2008
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 19 (7) , 464-468
Characteristics of primary and late latent syphilis cases which were initially non-reactive with the rapid plasma reagin as the screening test
Summary The aim of the study was to determine the characteristics of primary and late latent syphilis cases that were non-reactive on initial screening by rapid plasma reagin (RPR) but reactive by treponemal tests. RPR test results of all primary and late latent syphilis cases in the province of Alberta, Canada during 1980–2001 were compiled. The proportion of syphilis cases that were non-reactive by RPR testing was compared with reactive cases. Multiple logistic regression was used to identify factors associated with non-reactive RPR results. Among primary syphilis cases, 224 (26%) were non-reactive on initial RPR and were compared with 639 reactive primary cases. Independent factors associated with a non-reactive result were male gender (odds ratio, [OR] = 1.99 [1.22–3.26]), Caucasian ethnicity (OR = 1.77 [1.20–2.61]) and diagnosis during the 1980–1986 syphilis outbreak period in Alberta (OR = 3.13 [1.45–6.74]). Of the late latent cases, 512 (39%) were non-reactive by RPR and 791 were reactive. A non-reactive test for late latent cases was associated with male gender (OR = 2.91 [2.15–3.94]), Canadian Aboriginal (OR = 2.91 [1.59–5.32]), Caucasian (OR = 1.87 [1.35–2.58]), black ethnicity (OR = 1.76 [1.28–2.42]) and diagnosis during the 1980–1986 Alberta syphilis outbreak (OR = 1.67 [1.29–2.16]). RPR testing alone is insufficient to diagnose primary and late latent infections under certain conditions and patient characteristics. Case detection was lower for late latent syphilis when compared with primary syphilis based on the properties of the RPR. Further studies are needed to inform the optimal use of the RPR test in laboratory testing algorithms for the diagnosis of syphilis and to determine the cost effectiveness of better screening tests for syphilis.
- 1 July 2008
- Published by SAGE Publications in International Journal of STD & AIDS
- Vol. 19 (7) , 464-468
Characteristics of primary and late latent syphilis cases which were initially non-reactive with the rapid plasma reagin as the screening test
Summary The aim of the study was to determine the characteristics of primary and late latent syphilis cases that were non-reactive on initial screening by rapid plasma reagin (RPR) but reactive by treponemal tests. RPR test results of all primary and late latent syphilis cases in the province of Alberta, Canada during 1980–2001 were compiled. The proportion of syphilis cases that were non-reactive by RPR testing was compared with reactive cases. Multiple logistic regression was used to identify factors associated with non-reactive RPR results. Among primary syphilis cases, 224 (26%) were non-reactive on initial RPR and were compared with 639 reactive primary cases. Independent factors associated with a non-reactive result were male gender (odds ratio, [OR] = 1.99 [1.22–3.26]), Caucasian ethnicity (OR = 1.77 [1.20–2.61]) and diagnosis during the 1980–1986 syphilis outbreak period in Alberta (OR = 3.13 [1.45–6.74]). Of the late latent cases, 512 (39%) were non-reactive by RPR and 791 were reactive. A non-reactive test for late latent cases was associated with male gender (OR = 2.91 [2.15–3.94]), Canadian Aboriginal (OR = 2.91 [1.59–5.32]), Caucasian (OR = 1.87 [1.35–2.58]), black ethnicity (OR = 1.76 [1.28–2.42]) and diagnosis during the 1980–1986 Alberta syphilis outbreak (OR = 1.67 [1.29–2.16]). RPR testing alone is insufficient to diagnose primary and late latent infections under certain conditions and patient characteristics. Case detection was lower for late latent syphilis when compared with primary syphilis based on the properties of the RPR. Further studies are needed to inform the optimal use of the RPR test in laboratory testing algorithms for the diagnosis of syphilis and to determine the cost effectiveness of better screening tests for syphilis.
- Open Access
- 1 January 2008
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 19 (4) , 294-296
Human Papillomavirus Vaccines: Why the Time is Right to Implement Immunization and Surveillance Programs in Canada
- 1 January 2008
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 19 (4) , 294-296
Open AccessHuman Papillomavirus Vaccines: Why the Time is Right to Implement Immunization and Surveillance Programs in Canada
- Open Access
- 15 December 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (12) , 1640-1643
HIV Seroprevalence among Women Opting Out of Prenatal HIV Screening in Alberta, Canada: 2002-2004
Alberta, Canada, uses an “opt-out” strategy for prenatal HIV testing. We examined demographic characteristics of and HIV seroprevalence among women opting out. The proportion of total specimens that were from women who opted out decreased from 4.3% in 2002 to 3.6% in 2004 (P < .001), and HIV seroprevalence among these specimens was 0.07%, which was 3.3 times higher than the HIV seroprevalence among specimens from women who opted in. Women opting out may have a higher HIV infection risk.
- 15 December 2007
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 45 (12) , 1640-1643
Open AccessHIV Seroprevalence among Women Opting Out of Prenatal HIV Screening in Alberta, Canada: 2002-2004
Alberta, Canada, uses an “opt-out” strategy for prenatal HIV testing. We examined demographic characteristics of and HIV seroprevalence among women opting out. The proportion of total specimens that were from women who opted out decreased from 4.3% in 2002 to 3.6% in 2004 (P < .001), and HIV seroprevalence among these specimens was 0.07%, which was 3.3 times higher than the HIV seroprevalence among specimens from women who opted in. Women opting out may have a higher HIV infection risk.
- 1 May 2007
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 98 (3) , 194-197
Outcomes from a Canadian Public Health Prenatal Screening Program for Hepatitis B
Without appropriate prophylaxis, the rate of vertical transmission of hepatitis B virus (HBV) can be as high as 95%. Alberta’s provincial prenatal program screens all pregnant women for HBV, and provides prophylaxis to infants born to HBV-infected women. Canadian data on the outcomes of such programs are limited.
- 1 May 2007
- Published by Springer Nature in Canadian Journal of Public Health
- Vol. 98 (3) , 194-197
Outcomes from a Canadian Public Health Prenatal Screening Program for Hepatitis B
Without appropriate prophylaxis, the rate of vertical transmission of hepatitis B virus (HBV) can be as high as 95%. Alberta’s provincial prenatal program screens all pregnant women for HBV, and provides prophylaxis to infants born to HBV-infected women. Canadian data on the outcomes of such programs are limited.
- 1 February 2005
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 32 (2) , 95-100
Herpes Simplex Virus Seroprevalence and Risk Factors in 2 Canadian Sexually Transmitted Disease Clinics
The objectives of this study were to determine the seroprevalence and risk factors for herpes simplex virus (HSV) types 1 and 2 in patients attending 2 Canadian sexually transmitted disease (STD) clinics. Stored sera were tested for the presence of IgG class antibodies to HSV-1 and HSV-2 and results linked to that obtained from a risk behavior questionnaire. Overall prevalences for HSV-1 and -2 were 56% and 19%, respectively. HSV-1 and -2 seropositivity was associated with increasing age, female gender, nonwhite ethnicity, and a history of STD. HSV-2 seropositivity was also associated with a history of genital herpes, presence of genital sores, and coinfection with either human immunodeficiency virus (HIV) or hepatitis C (HCV). Herpes simplex infection is common in this high-risk Canadian population. Our finding that HCV seropositivity was a significant predictor for HSV-2 seropositivity emphasizes the overlap between pathogens that are primarily thought to be bloodborne pathogens and sexually transmitted infections and the need to target prevention in these areas concurrently.
- 1 February 2005
- Published by Wolters Kluwer Health in Sexually Transmitted Diseases
- Vol. 32 (2) , 95-100
Herpes Simplex Virus Seroprevalence and Risk Factors in 2 Canadian Sexually Transmitted Disease Clinics
The objectives of this study were to determine the seroprevalence and risk factors for herpes simplex virus (HSV) types 1 and 2 in patients attending 2 Canadian sexually transmitted disease (STD) clinics. Stored sera were tested for the presence of IgG class antibodies to HSV-1 and HSV-2 and results linked to that obtained from a risk behavior questionnaire. Overall prevalences for HSV-1 and -2 were 56% and 19%, respectively. HSV-1 and -2 seropositivity was associated with increasing age, female gender, nonwhite ethnicity, and a history of STD. HSV-2 seropositivity was also associated with a history of genital herpes, presence of genital sores, and coinfection with either human immunodeficiency virus (HIV) or hepatitis C (HCV). Herpes simplex infection is common in this high-risk Canadian population. Our finding that HCV seropositivity was a significant predictor for HSV-2 seropositivity emphasizes the overlap between pathogens that are primarily thought to be bloodborne pathogens and sexually transmitted infections and the need to target prevention in these areas concurrently.
- Open Access
- 1 January 2005
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 16 (2) , 92-98
The Laboratory Diagnosis of Herpes Simplex Virus Infections
Herpes simplex virus (HSV) types 1 and 2 cause genital herpes infections and are the most common cause of genital ulcer disease in industrialized nations. Although these infections are very common, the majority of them remain underdiagnosed because they are asymptomatic or unrecognized. A clinical diagnosis of genital herpes should always be confirmed by laboratory testing; this can be accomplished through the use of direct tests for viral isolation, the detection of antigen or, more recently, the detection of HSV DNA using molecular diagnostic techniques. Testing for serotypes is recommended because of the different prognostic and counselling implications. Type‐specific HSV serology is becoming more readily available and will enhance the ability to make the diagnosis and guide clinical management in select patients.
- 1 January 2005
- Published by Wiley in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 16 (2) , 92-98
Open AccessThe Laboratory Diagnosis of Herpes Simplex Virus Infections
Herpes simplex virus (HSV) types 1 and 2 cause genital herpes infections and are the most common cause of genital ulcer disease in industrialized nations. Although these infections are very common, the majority of them remain underdiagnosed because they are asymptomatic or unrecognized. A clinical diagnosis of genital herpes should always be confirmed by laboratory testing; this can be accomplished through the use of direct tests for viral isolation, the detection of antigen or, more recently, the detection of HSV DNA using molecular diagnostic techniques. Testing for serotypes is recommended because of the different prognostic and counselling implications. Type‐specific HSV serology is becoming more readily available and will enhance the ability to make the diagnosis and guide clinical management in select patients.